The ALULA monoclonal antibody specifically binds to Integrin alpha v beta 5 (αvβ5), which is also known as CD51/β5. Integrin αvβ5 is widely expressed by fibroblasts, endothelial cells, and vascular smooth muscle cells. It is involved in activation-dependent cell migration and cell adhesion to the extracellular matrix. Integrin αvβ5 plays a major role in growth factor-induced angiogenesis in response to VEGF and TGF. The αv Integrins, αvβ5 and αvβ3, αre involved in tumor growth and are being targeted in cancer therapies. The ALULA clone specifically recognizes αvβ5 integrin and functionally blocks the interaction between αvβ5 and vitronectin. Although raised against mouse αvβ5, the ALULA antibody crossreacts with human αvβ5.
The antibody was conjugated to BD Horizon™ BUV661 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 661-nm. BD Horizon Brilliant BUV661 can be excited by the ultraviolet laser (355 nm) and detected with a 670/25 filter and a 630 nm LP. Due to cross laser excitation of this dye, there may be significant spillover into channels detecting APC-like emissions (eg, 670/25-nm filter).
Due to spectral differences between labeled cells and beads, using BD™ CompBeads can result in incorrect spillover values when used with BD Horizon BUV661 reagents. Therefore, the use of BD CompBeads or BD CompBeads Plus to determine spillover values for these reagents is not recommended. Different BUV661 reagents (eg, CD4 vs. CD45) can have slightly different fluorescence spillover therefore, it may also be necessary to use clone-specific compensation controls when using these reagents.